The study was conducted to evaluate the therapeutic and adverse effects of oxaliplatin combination therapy with capecitabine in the treatment of Colorectal cancer stage II at high risk, Cancer phase III and Metastatic cancer; Identify the factors that affect the outcome of this treatment.

At present, Cantho Oncology Hospital as well as some other cancer facilities have used Oxaliplatin combination with Capecitabine for postoperative supportive treatment for colorectal cancer stage II, stage III and metastatic colorectal cancer, but there is no adequate research on the outcome and the undesirable effects of this treatment regimen.

A total of 226 patients were diagnosed with advanced stage II Colorectal cancer and metastasized cancer at Cantho Oncology Hospital. Patients with histopathological results are epithelial carcinomas. Of these, 131 cases of colorectal cancer in early stage and 95 cases of metastatic colorectal cancer. Study period was from January 2012 to December 2016.

Results showed that chemotherapy supported the combination of oxaliplatin and capecitabine in stage II colon cancer, stage III cancer with high survival. In which, the non-disease survival rate was 82.7% for 3 years and the average life expectancy without disease was 37.4 months. The overall survival rate of all three years was 86.8% and the median total survival was 39.2 months.

Chemotherapy of oxaliplatin combined capecitabine in metastatic colorectal metastatic cancer has a higher rate of response and survival. The overall response rate was 46.4%, in which the complete response was 5.3%, responding in part was 41.1%. Disease stability was 28.4% and 25.3% progressive disease. The duration of non-progressive disease was 9.8 months, with a total duration of 18.2 months. Survival rate without disease progression one year was 33.7%, live a whole year was 82.1%.

In the early stage of colorectal cancer, chemotherapy supported the delivery of oxaliplatin plus capecitabine with acceptable toxicity. There were 70.1 patients affected by the toxins, the toxicity was usually mild, only 16.1% toxicity at level 3-4. Hematologic toxicity such as leukopenia at the level 3-4 was 31%. Toxicity on the digestive tract, nervous system, skin, was mainly mild level, most recovered patients after stopping treatment.

In treatment of metastatic colorectal cancer,  76.8% of patients were affected by the toxicity, of which the degree of toxicity of 3-4 was 26.3%. Toxicity on digestive system, nervous system, skin was mainly at 1-2 degree. Toxicity on hematopoietic system was mainly in 1-2, degree 3-4 only 15.3%. Toxicity on the liver, kidneys mainly in 1-2, 3-4 degrees was 0.8%.

The acceptance Council has evaluated the study for excellence. However the research team needs to add an abstract of the report, research papers published in the journal, etc.